These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 18922615)

  • 1. Erythropoietins: a common mechanism of action.
    Elliott S; Pham E; Macdougall IC
    Exp Hematol; 2008 Dec; 36(12):1573-84. PubMed ID: 18922615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role.
    Agoram B; Aoki K; Doshi S; Gegg C; Jang G; Molineux G; Narhi L; Elliott S
    J Pharm Sci; 2009 Jun; 98(6):2198-211. PubMed ID: 18837016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
    Fan Q; Leuther KK; Holmes CP; Fong KL; Zhang J; Velkovska S; Chen MJ; Mortensen RB; Leu K; Green JM; Schatz PJ; Woodburn KW
    Exp Hematol; 2006 Oct; 34(10):1303-11. PubMed ID: 16982323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of rHuEPO biological activity: the role of carbohydrate.
    Elliott S; Egrie J; Browne J; Lorenzini T; Busse L; Rogers N; Ponting I
    Exp Hematol; 2004 Dec; 32(12):1146-55. PubMed ID: 15588939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietic agents and the elderly.
    Agarwal N; Prchal JT
    Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.
    Salahudeen AK; Haider N; Jenkins J; Joshi M; Patel H; Huang H; Yang M; Zhe H
    Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1354-65. PubMed ID: 18385271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of darbepoetin alfa.
    Macdougall IC; Padhi D; Jang G
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv2-iv9. PubMed ID: 17526547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL; McKenzie RS; Fastenau J; Piech CT
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
    Okonko DO; Marley SB; Anker SD; Poole-Wilson PA; Gordon MY
    Int J Cardiol; 2013 Apr; 164(3):359-64. PubMed ID: 21821297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of epoetin alfa in critically ill patients.
    Pajoumand M; Erstad BL; Camamo JM
    Ann Pharmacother; 2004 Apr; 38(4):641-8. PubMed ID: 14966258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and erythropoiesis stimulating agents.
    Debeljak N; Sytkowski AJ
    Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.